´ëÇѹæ»ç¼±Á¾¾çÇÐȸ 2022³â 40Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2022-10-13±³À°ÀÏÀÚ : 2022-10-13
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ(¼Ò°øµ¿)
±³À°ÁÖÁ¦ :
2022³â 40Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ
´ã´çÀÚ : ÃÖÇýÁø
¿¬¶ôó : 02-743-6574
À̸ÞÀÏ :
kosro@kosro.or.kr ±³À°Á¾·ù : ¹æ»ç¼±Á¾¾çÇаú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í ¿ø·Îȸ¿ø:¹«·á Á¤È¸¿ø(Àü¹®ÀÇ) : 80,000¿ø ¼ö·Ãȸ¿ø : 50,000¿ø Ưº°È¸¿ø(ÀÇÇй°¸®/»ý¹°¹Ú»ç) : 50,000¿ø ÁØȸ¿ø : 30,000¿ø ºñȸ¿ø : 120,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 09:30~10:30 Radiation Oncologist Silvia Formenti(Weill Cornell Medicine)
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 10:30~11:10 Medical Oncologist ±èÅÂÀ¯(¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 11:10~11:50 Recent trends in tumor immunology ½ÅÀÇö(Çѱ¹°úÇбâ¼ú¿ø)
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 11:50~12:00 Circulating tumor HPV-DNA kinetics in p16+ oropharyngeal cancer patients undergoing adaptive radiation de-escalation based on mid-treatment nodal response Joseph Kim(NYU Langone Health)
ÈÞ½Ä 10-13 ·Ôµ¥È£ÅÚ 11:50~13:00 ÈÞ½Ä ()
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 13:00~13:50 Radiation Dose De-escalation Strategy in Definitive Concurrent Chemoradiotherapy for nasopharyngeal cancer ¹®Áø¿µ(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 13:50~14:40 Impact of the new ESTRO-ACROP target volume delineation guideline on breast-related complications after implant-based reconstruction and postmastectomy radiotherapy ¹ÚÁ¤ºó(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 14:40~15:30 Development of a new treatment modality to reduce post-radiation proctitis in prostate cancer: Magnetic Modulated Radiation Therapy (MMRT) Á¤´©¸®Çö(°¿ø´ëÇб³º´¿ø)
ÈÞ½Ä 10-13 ·Ôµ¥È£ÅÚ 15:30~15:50 ÈÞ½Ä ()
±³À°½Ã°£ 10-13 ·Ôµ¥È£ÅÚ 15:50~17:05 Theragnostics: Recent updates in Radionuclide Therapy õ±âÁ¤(¼¿ï´ëÇб³)